Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Mayne Pharma Group ( (AU:MYX) ) just unveiled an update.
Mayne Pharma Group announced that the Foreign Investment Review Board (FIRB) has extended the deadline for approval of its acquisition by Cosette Pharmaceuticals to 14 November 2025. The acquisition, structured as a scheme of arrangement, still requires FIRB and court approvals. If approved, Mayne Pharma shares will be suspended from trading on 19 November 2025, with the scheme implementation date set for 1 December 2025. The extension may impact the timeline of the acquisition, but Mayne Pharma will keep stakeholders informed of any changes.
The most recent analyst rating on (AU:MYX) stock is a Sell with a A$4.50 price target. To see the full list of analyst forecasts on Mayne Pharma Group stock, see the AU:MYX Stock Forecast page.
More about Mayne Pharma Group
Mayne Pharma is an ASX-listed specialty pharmaceutical company that focuses on commercializing novel pharmaceuticals, particularly in dermatology and women’s health in the United States. The company also provides contract development and manufacturing services globally and has a 40-year history of innovation in oral drug delivery systems.
Average Trading Volume: 440,900
Technical Sentiment Signal: Sell
Current Market Cap: A$372.1M
See more insights into MYX stock on TipRanks’ Stock Analysis page.